minor stroke – Medxy AI

Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Insights from the TEMPO-2 Trial

By MedXY 04/29/2026

Secondary analysis of TEMPO-2 trial data reveals intracranial hemorrhage in minor stroke patients increases 90-day mortality risk threefold, with higher hemorrhage rates in tenecteplase-treated patients despite most bleeds being non-symptomatic.

Neurology news Oncology

Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study

By MedXY 01/07/2026

A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in remission or without cancer.

Internal Medicine Neurology news

The 42-Hour Window: Why Delaying Dual Antiplatelet Therapy Compromises Outcomes in Minor Stroke and High-Risk TIA

By MedXY 01/07/2026

A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hours.

Neurology news

Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese Registry

By MedXY 10/29/2025

A nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved functional outcomes.

Clinical Updates Neurology news Specialties

Nine-Year Outcomes After Lacunar and Mild Cortical Ischemic Stroke: Long-Term Functional, Cognitive, and Vascular Impacts

By MedXY 08/26/2025

This longitudinal study reveals persistent cognitive, physical, and vascular challenges up to 9 years after minor lacunar or cortical ischemic stroke, emphasizing different risks and recovery patterns by stroke subtype.